Clinical

Dataset Information

0

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer


ABSTRACT: This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.

DISEASE(S): Dmmr Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 46532 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-04-07 | GSE149206 | GEO
| 64137 | ecrin-mdr-crc
| 2736356 | ecrin-mdr-crc
| 2352126 | ecrin-mdr-crc
| 58600 | ecrin-mdr-crc
| PRJNA627657 | ENA
| PRJEB53321 | ENA
| 2346468 | ecrin-mdr-crc
2021-07-19 | GSE178706 | GEO
| 114549 | ecrin-mdr-crc